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A strategy was developed to isolate Nanobodies, camelid-derived single-domain antibody fragments, against the parasite
infectome without a priori knowledge of the antigens nor having access to the purified antigens. From a dromedary, infected with
T. evansi, we cloned a pool of Nanobodies and selected after phage display 16 different Nanobodies specific for a single antigen,
i.e. variant surface glycoprotein of T. evansi. Moreover 14 Nanobodies were isolated by panning on different total parasite lysates.
Thus, this anti-infectome experiment generated Nanobodies, monospecific for one Trypanosoma species, whereas others were pan-
reactive to various Trypanosoma species. Several Nanobodies could label specifically the coat of a set of Trypanozoon species. The
recognized target(s) are present in GPI-linked membrane fractions of bloodstream- and fly-form parasites. Due to the omnipresence
of these targets on different parasite species and forms, these antibody fragments are a valuable source for validation of novel, not
yet identified targets to design new diagnostics and therapeutics.
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The functional analysis of proteomes necessitates
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doi:10.1016/j.jim.2007.10.0052005). Antibodies are considered to be the first choice
for such molecular recognition units (De Masi et al.,
2005). To keep up with the vast number of targets
envisaged for functional analysis, high-throughput
techniques should be introduced to arrive at a
representative set of reporter molecules against a
(subset) of the proteome (Huang et al., 2002). However,
(i) the availability of the target proteins and (ii)
possessing over diverse libraries from which to retrieve
binders are even more important. Phage- or ribosome
display of large non-immune, i.e. synthetic or naïve,
antibody libraries allows the screening of up to 1012
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selected target to retrieve binders (Smith and Petrenko,
1997; Schaffitzel et al., 1999; Azzazy and Highsmith,
2002). In this approach the target should be available in a
purified form either from a recombinant source or
extracted from the proteome. It is clear that a direct
screening of antibody libraries against an antigen
mixture or a complete proteome to identify a maximum
number of antigen-specific binders without an absolute
need for antigen purification would constitute a serious
improvement (Wingren et al., 2005). A second bottle-
neck comes from the weak affinity/specificity of the
selected reporter molecules. Although the combination
of large libraries and display techniques should theoreti-
cally yield antibodies of high affinity (in the nanomolar
range) and high specificity towards the selected target,
these are not routinely retrieved (Nakayama et al., 2001;
Azzazy and Highsmith, 2002). Improving the antigen-
binding property of a primary selected antibody is a very
laborious task and the outcome remains unpredictable.
Therefore, other approaches to directly isolate antibodies
of high specificity and affinity, against multiple targets
would be very welcome in the field of functional
proteomics.
A possible way to improve on the low affinity of
retrieved antibodies would consist in the employment of
immune libraries. The immunization with a proteome or
a complex mixture of antigens is expected to generate
antibodies in the (sub-) nanomolar range against
multiple antigens (Sakakibara et al., 2005). The com-
bination of immunization and subtractive panning
procedures were successfully employed to obtain anti-
bodies towards specific targets of the proteome
(Zampieri et al., 2003; Zijlstra et al., 2003; Hof et al.,
2005). Different antibodies in a scFv or Fab format
could be isolated from patients with auto-immune
diseases (Farnaes and Ditzel, 2003; Zampieri et al.,
2003), cancers (Rothe et al., 2004), or infections (Reiche
et al., 2002; Kausmally et al., 2004; Ludewig et al.,
2004). Although the method seems to work (Tur et al.,
2003; Kramer et al., 2005), the scFv or Fab library
construction is rather complex as the original VH–VL
combined domains, matured as a pair during the
immunization, are scrambled during the cloning proce-
dure. In this respect, the retrieval of single-domain
antibody fragments (VHH or Nanobody) from camelids
immunized with a total proteome from a particular cell
population or from a cell or tissue extract should
facilitate the protocol. Cloning the repertoire of antigen-
binding fragments from camelids in a phage display
vector has an important advantage, since the binding
repertoire of the unique Heavy-chain antibodies in theseanimals is encoded by only a single exon in contrast to
two exons for antibodies of other mammals. Conse-
quently, for an immune VHH library, a size of 106 is
already sufficient for the identification of antigen-
specific single-domain binders (Muyldermans, 2001).
Moreover, the camelid immune system routinely gene-
rates in vivo maturated antibodies of (sub-) nanomolar
affinity (Lauwereys et al., 1998; Conrath et al., 2001;
Saerens et al., 2004). The superior intrinsic properties,
e.g. higher in vitro stability (Dumoulin et al., 2002),
higher solubility (Muyldermans, 2001), and their ability
to target unique epitopes that differ from epitopes
recognized by VH–VL pairs (Lauwereys et al., 1998;
Ledeboer et al., 2002; De Genst et al., 2006), make
Nanobodies potent entities in functional proteomics.
Especially the latter feature is advantageous e.g. when
differentiation between isoforms (Saerens et al., 2004)
or recognition of cryptic epitopes (Stijlemans et al.,
2004) of the native protein is required.
In this work, we envisaged the identification of
single-domain antibodies against a Trypanosoma infec-
tome in dromedary. The Trypanosoma evansi parasites
cause trypanosomiasis or Surra, a major health and
economic problem in developing countries (Wernery
and Kaaden, 2002). An infection with a species within
the Trypanozoon subgenus comprising T. brucei,
T. evansi and T. equiperdum was chosen as model
since there is a definite need for better diagnostic and
therapeutic tools to combat these infectious agents
(Hutchinson et al., 2004; Chretien and Smoak, 2005).
The major problem consists of the antigenic variation
strategy adopted by the parasite (Donelson, 2003; Pays
et al., 2004; Dubois et al., 2005). This immune evasion
strategy allows for the prolonged survival of the parasite
in the host and is mediated by the variant surface
glycoprotein (VSG) on the outer membrane of the para-
site (Pays et al., 2004; Dubois et al., 2005). Although the
antibody immune response mounted by the host is not
protective against the infection, functional information
about the interplay between parasite and host might be
gained from its analysis (Mitchell and Pearson, 1986).
Since the infectious agent or pathogen triggers the
antibody generation, these antibodies might react with
clinically significant parasite antigens, e.g. for identifi-
cation of antigenic epitopes involved in the humoral
response (Azzazy and Highsmith, 2002). For diagnostic
and therapeutic purposes, it is essential to possess over
both Trypanosoma species-specific antibodies (e.g.
VSG-specific) and antibodies pan-reactive to multiple
Trypanosoma species. Both these types of antibodies
were isolated in a single-domain format from lympho-
cytes of a dromedary infected with T. evansi.
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2.1. Infection of a dromedary
One dromedary (Camelus dromedarius) kept at the
Central Veterinary Research Laboratory (Dubai, U.A.E.)
was infected with T. evansi (T. CVRL, approximately
3×106 live parasites), isolated from a camel in the
Emirate of Dubai and passed three times in white
laboratory mice. Three months after infection of the
dromedary, 50 ml of anti-coagulated blood was
collected, from which plasma and peripheral blood
lymphocytes were isolated (WAK Chemie).
2.2. Purification of Trypanosoma antigens
Male C57B1/6 mice between six to eight weeks old
were injected with different Trypanosoma species
(Table 1). Blood was collected five to seven days
post-injection and the parasites were isolated from the
blood on DEAE-52 resin (Lanham and Godfrey, 1970).
Different kinds of antigen fractions were extracted from
the parasites: (a) the total parasite lysate, (b) the
glycosyl–phosphatidyl–inositol (GPI)-anchored mem-
brane protein fraction, and finally (c) the soluble variant
surface glycoprotein (sVSG).
(a) For the total parasite lysate, 109 isolated parasites
were resuspended in 1 ml PBS and sonicated 3 times
for 30 s (Stijlemans et al., 2004). The destruction of
parasites was confirmed microscopically. The lysed
parasites were centrifuged at 14,000 RPM, 4 °C for
30 min and the soluble parasite lysate was obtained
from the supernatant.Table 1
Origin of Trypanosoma's
Trypanosoma Origin
T. evansi (T. CVRL) Isolated from a camel and used for
infection of a dromedary (Dubai, UAE)
T. evansi Kenya Kenya
T. evansi ITMAS Camel from Kenya
T. evansi KETRI Kenya
T. congolense Tc13 Provided by Dr. H. Tabel, Canada
T. b. brucei AnTat 1.1 Provided by Institute of Tropical
Medicine Antwerp (Belgium)
T. b. brucei MiTat 1.2 Variant of 427 T. b. brucei
T. b. brucei MiTat 1.5 Variant of 427 T. b. brucei
T. b. rhodesiense ETat 1.2 Uganda
T. b. gambiense FEO Provided by Prof. Vincendeau, France
T. b. gambiense ABBA Provided by Prof. E. Pays, Belgium
T. vivax ILRAD-700 Provided by Institute of Tropical
Medicine Antwerp (Belgium)(b) For the GPI-anchored membrane protein fraction,
a combination of previously described protocols
(Cross, 1984; Schell and Overath, 1990) was fol-
lowed and described in full detail by Stijlemans et al.
(2007). Briefly, 3×109 parasites were resuspended in
(8 ml) ice cold PBS and protease inhibitor solution
(2 mM TLCK, 1 tablet complete-protease inhibitor
from Roche supplemented with 20 mM p-chloro-
mercurybenzenesulphonic acid (PCMBS, Sigma) as
inhibitor of the PLC), and incubated for 30 min on ice
followed by a 3 times incubation exchange from
liquid nitrogen to 37 °C. Parasites were pelleted and
resuspended in solution A (100 mM Hepes, NaOH
pH 6.9, 10 mM PCMBS (Sigma), 1 mM TLCK,
0.1 mM PMSF). The soluble part was removed by
ultracentrifugation (Centrikon T-2070 rotor, BRS,
Belgium) (100,000 g, 30 min, 4 °C) and the
pellet was resuspended in solution A containing 2%
n-octylglucopyranoside (Roche) for 45 min on ice.
Following a final ultracentrifugation step (100,000 g,
60 min, 4 °C) the GPI-linked membrane fraction was
stored at −20 °C.
(c) For the sVSG preparation, an additional fraction-
ation of the GPI-linked membrane protein fraction
was performed by anion exchange chromatography
in 100 mM NaCl solution (Cross, 1975). The purity
of the sVSG containing fractions was checked by
SDS-PAGE and Coomassie staining or on Western
blot with a rabbit anti-VSG polyclonal antiserum. All
antigens were stored at −20 °C until further use.
2.3. Fractionation of IgG subclasses
Separation of the different plasma dromedary IgG
subclasses was performed by differential adsorption on
Hitrap-protein A and Hitrap-protein G columns (Amer-
sham Biosciences) as described previously (Hamers-
Casterman et al., 1993).
2.4. Library construction
The mRNA was extracted from the peripheral blood
lymphocytes with Quickprep™ micro mRNA purifica-
tion kit (Amersham Biosciences). In a subsequent step
the cDNAwas prepared using Ready-to-Go You-prime-
first-strand-beads (Amersham Biosciences). The gene
fragments encoding the variable domain until the CH2
domain were amplified, with the specific primers
CALL001 (5′-GTC CTG GCT CTC TTC TAC AAG
G-3′) and CALL002 (5′-GGT ACG TGC TGT TGA
ACT GTT CC-3′), annealing at the leader sequence and
within the CH2 exon of the H-chains of all dromedary
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without CH1 exon representative for all H-genes of
Heavy-chain antibodies) was eluted from a 1% agarose
gel after separation from the 900 bp fragment (VH–
CH1–CH2 exons, representative for the H-genes of
classical antibodies). Since all VHHs belong to the same
gene family (the homologue of family III in human),
they are amplified with one additional PCR with nested
primers A4short (5′-CAT GCC ATG ACT CGC GGC
CCA GCC GGC CAT GGC-3′) and 38 (5′-GGA CTA
GTG CGG CCG CTG GAG ACG GTG ACC TGG GT-
3′) annealing at the framework-1 and framework-4
regions, respectively. The final PCR fragments were
ligated into the phagemid vector pHEN4 (Arbabi
Ghahroudi et al., 1997), after cutting with the restriction
enzymesNcoI andNotI. Ligatedmaterial was transformed
in freshly prepared E. coli TG1 cells and plated on LB
plateswith ampicillin. The colonieswere scraped from the
plates, washed and stored at −80 °C in LB-medium
supplemented with glycerol (50% final concentration).
2.5. Selection of specific antibody fragments
The Nanobody library was expressed on phage after
super-infection with M13K07 helper phages. Specific
Nanobodies (attached on virions) were enriched by
several consecutive rounds of in vitro selection on
different antigen preparations coated either on wells of
microtiter plates or on immunotubes (Nunc). Bound
phage particles were eluted with 100 mM Triethylamine
(pH 11.0). The eluted particles were immediately
neutralized with 1 M Tris–HCl (pH 7.4) and used to
infect exponentially growing E. coli TG1 cells. The
enrichment of phage particles carrying the antigen-
specific Nanobodies was assessed by comparing the
number of phages eluted from wells with captured
versus non-captured antigen (Parmley and Smith, 1988).
Individual colonies were picked and expression of
recombinant phage particles or soluble periplasmic
Nanobody was performed by super-infection with
M13K07 or addition of 1 mM isopropyl-β-D-thiogalac-
topyranoside (IPTG), respectively. The supernatant or
periplasmic extract was tested in ELISA for antigen
recognition by the Nanobody attached to phage particles
or soluble Nanobody, respectively.
2.6. Expression and purification of antibody fragments
The VHH genes of the clones that scored positive in
ELISA were recloned into the expression vector
pHEN6 (Conrath et al., 2001), using the restriction
enzymes NcoI and BstEII. The plasmid constructs weretransformed into E. coli WK6 (su−) cells. Expression
in the periplasm and purification of Nanobody was
performed as described previously (Conrath et al.,
2001).
2.7. Solid-phase ELISA
Maxisorb 96-well plates (Nunc) were coated over-
night at 4 °C with different antigen preparations at 1–
10 μg ml−1 in PBS. Residual protein binding sites in the
wells were blocked for two hours at room temperature
with 1% casein or 1% milk in PBS. Serial dilutions of
purified IgG subclasses, virions from different rounds of
panning or Nanobodies were added to the wells.
Detection of antigen-bound IgG, M13 virions, or
Nanobody was performed with a rabbit anti-drome-
dary-IgG antiserum, a horse-radish peroxidase-anti-M13
conjugate (Amersham Biosciences), a mouse anti-
haemaglutinin-decapeptide-tag (BAbCO) or a mouse
anti-histidine-tag (Serotec), as appropriate. Subsequent
detection of the rabbit antiserum or the mouse anti-tag
antibodies was done with an alkaline phosphatase anti-
rabbit-IgG or anti-mouse-IgG conjugate (Sigma), re-
spectively. The absorption at 405 nm was measured
15 min after adding the enzyme substrate p-nitrophenyl
phosphate or 2, 2′-azino-bis (3-ethylbenzathiazoline-6-
sulfonic acid) for phosphatase or peroxidase conjugates,
respectively.
2.8. Flow cytometry analysis
Purified Nanobodies were labeled with Alexa Fluor
488 according to the manufacturer's instructions
(Molecular Probes). The bloodstream form of the Try-
panosoma was used in FACS. Either the parasites were
fixed with a PBS solution (containing 3% formaldehyde
and 1% glutaraldehyde) before (fixed parasites) or after
(living parasites) addition of labeled Nanobodies.
Aliquots of 2×106 purified parasites were incubated
with 5 μg labeled Nanobody. After 30 min parasites
were pelleted, the pellet was resuspended in 500 μl PBS
and pelleted again to remove unbound Nanobody. After
five of these washes the parasites were subsequently
analyzed in FACSvantage Fluorescence-Activated Cell
Sorter (Becton Dickinson, San Jose, CA).
3. Results
3.1. Antibody response towards soluble VSG (sVSG)
A dromedary was infected with T. evansi, isolated
from a camel and passed three times in white laboratory
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blood was taken from the infected dromedary and the
conventional (IgG1) and Heavy-chain (IgG2, IgG3)
antibodies were fractionated from the plasma by
differential absorption on protein A and G (Hamers-
Casterman et al., 1993). Since the host is primarily
confronted with a huge amount of VSG molecules
exposed on −, or released from the parasites' surface
(Dubois et al., 2005), these fractionated IgGs were
tested on several sVSG proteins from different Trypa-
nosomas. The sVSG proteins, prepared from either
T. evansi Kenya or T. b. brucei AnTat 1.1, were
recognized in solid-phase ELISA by Heavy-chain and
conventional antibodies (Fig. 1). This indicates that an
immune response to the sVSG antigens is raised in the
dromedary classical — and Heavy-chain antibodies.
Furthermore, for all three IgG fractions, the signal to
sVSG from T. evansi Kenya was higher than that to the
sVSG from T. b. brucei AnTat 1.1.
3.2. Nanobody library construction
A Nanobody library starting from 1.5×107 lympho-
cytes was cloned in a phage display vector according to
Saerens et al. (2004). Based on test ligations of vector to
PCR fragment, a molar ratio of one to three appeared
optimal for construction of the library. Approximately
3 μg of the ligated vector were transformed in E. coli
cells (TG1) to obtain a library of 107 individual
transformants. As determined by colony PCR, 75% of
the clones in this library contained an insert with a size
of a VHH gene.Fig. 1. The IgG response of infected dromedary measured by solid-phase EL
and T. b. bruceiAnTat 1.1 (open symbols), bound IgG1 (■), IgG2 (●) and IgG
at 405 nm was measured 15 min after addition of substrate.3.3. Selection and characterization of sVSG-specific
Nanobodies
The isolation of sVSG-specific Nanobodies was
performed by four consecutive rounds of in vitro
selection on solid-phase coated T. evansi Kenya
sVSG. Specific enrichment to T. evansi Kenya sVSG
was observed starting from the third round of selection
(results not shown). Twenty-four individual clones
(randomly selected) from the second, third and fourth
round of panning were used for expression of soluble
Nanobodies. The capacity of these Nanobodies to bind
sVSG from T. evansi Kenya was assessed by ELISA.
After HinfI RFLP and sequence analysis on the VHH
genes amplified from the clones positive in ELISA, 16
different Nanobodies against T. evansi Kenya sVSG
were identified (Fig. 2A, NbTev clones).
The four NbTev (i.e. E25, E28, E60 and E62) giving
the highest signals in ELISA, were chosen for further
analysis. Both NbTev-E25 and E28 have a homologous
CDR1 and large similarities in their CDR3 of 15 amino
acids, whereas NbTev-E60 and E62 harbor longer
CDR3 loops of 17 and 21 amino acids, respectively.
These Nanobodies were expressed in E. coli periplasm
and purified by IMAC and size-exclusion chromatog-
raphy. Purified Nanobody (N95% pure) could be
obtained in yields between 0.5 to 3 mg Nanobody per
liter of E. coli culture.
The alloreactivity towards sVSG proteins from T. b.
bruceiAnTat 1.1, T. b. bruceiMiTat 1.5, T. b. rhodesiense
ETat 1.2 and T. congolense Tc13 was tested. Apparently,
the four NbTev were specific for the sVSG from T. evansiISA. After coating soluble VSG from T. evansi Kenya (filled symbols)
3 (▲) was detected with rabbit anti-dromedary IgG antiserum. The OD
Fig. 2. Amino acid sequence alignment of isolated Nanobodies with cAbBCII10 according to IMGT (http://imgt.cines.fr/) and Kabat numbering (Kabat et al., 1991). The Nanobodies specific for
T. evansi Kenya sVSG (A) and crossreacting with parasite lysate (B) are denoted as NbTev and NbTRYP, respectively.
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Fig. 3. (A) Solid-phase ELISA coating sVSG from T. evansi Kenya (■), T. b. brucei AnTat 1.1 (●), T. b. bruceiMiTat 1.5 (▲), T. b. rhodesiense ETat
1.2 (▼) and T. congolense Tc13 (◆), and subsequent recognition by NbTev-E60. (B) The NbTev-E25 (■), E28 (●), E60 (▲) and E62 (▼) were
coated at 10 μg ml−1 in PBS. Subsequently, the T. evansi Kenya sVSG was loaded in serial dilution from 1 μg ml−1 onwards. Captured T. evansi
Kenya sVSG was detected with polyclonal rabbit anti-VSG antiserum. The OD at 405 nm was measured 15 min after addition of substrate.
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(Fig. 3A, shows the representative data for NbTev-E60).
The potential of Nanobodies to capture sVSG from
solution was tested in a sandwich ELISA (Fig. 3B). The
four selected NbTev could easily capture sVSG from
solution at a concentration of 50 ng ml−1 which cor-
responds to a detection sensitivity of 4.6×104 parasites
per ml of blood. This detection sensitivity is similar to that
of other parasite detection techniques, such asHCTorAg-
ELISA (Kashiwazaki et al., 2000).
3.4. Antibody response against different Trypanosoma
lysates
In contrast to an immunization with purified proteins
that raises a monospecific immune response, the parasiteinfection of a dromedary should have elicited antibodies
to multiple Trypanosoma proteins in parallel. The
antibody response of this infected dromedary was
therefore assessed in an ELISA by using various total
parasite lysates as antigen. High or intermediate to low
signals largely depending on the parasite species were
noticed for the fractionated IgGs on these lysates. The
T. b. brucei AnTat 1.1 and T. evansi ITMAS lysate as
antigen gave only low signals for both, the conventional
IgG1 and the Heavy-chain IgG2 fractions. In contrast,
high signals were obtained for the Heavy-chain IgG3
subclass against T. b. brucei AnTat 1.1 (Fig. 4A). In fact
a similar picture was obtained previously when a
dromedary was immunized with sVSG from T. b. brucei
AnTat 1.1 (Stijlemans et al., 2004). In that experiment,
only the polyclonal Heavy-chain IgG3 antibodies (not
Fig. 4. The IgG response of infected dromedary to parasite lysates was measured by solid-phase ELISA. (A) After coating lysate from T. b. brucei
AnTat 1.1 (filled symbols) and T. evansi ITMAS (open symbols), bound IgG1 (■), IgG2 (●) and IgG3 (◆) was detected with rabbit anti-dromedary
IgG antiserum. The OD at 405 nm was measured 15 min after addition of substrate. (B) Total parasite lysate IgG3 immune response of the
Trypanosoma infected dromedary. The IgG response of infected dromedary to different parasite lysates was measured by solid-phase ELISA: T. b.
brucei AnTat 1.1 (■), T. b. rhodesiense ETat 1.2 (▼), T. b. gambiense FEO (◆), T. vivax (▲), T. evansi ITMAS (+) and T. congolense Tc13
(●). After coating lysate from different Trypanosoma lysates, bound IgG3 was detected with rabbit anti-dromedary IgG antiserum. The OD at 405 nm
was measured 15 min after addition of substrate.
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classes (AnTat1.1, MiTat 1.1 and MiTat 1.5) in a dot
blot. Therefore, we investigated the cross-reactivity of
the IgG3 fraction to lysates of different trypanosome
species (Fig. 4B). In line with the previous experiment
(Stijlemans et al., 2004), it is clear that the IgG3
fractions contain antibodies that reacted strongly with all
lysates (T. b. brucei AnTat 1.1, T. b. rhodesiense ETat
1.2, T. b. gambiense FEO, T. vivax, T. evansi ITMAS)
with the possible exception of T. congolense Tc13.
3.5. Panning on total parasite lysates and selection of
specific Nanobodies
Two panning procedures were followed for the
isolation of Nanobodies to the antigens within a total
parasite lysate. A first screening was performed using a
single T. b. brucei AnTat 1.1 lysate during all selection
rounds (Table 2, selection “A”). It was expected that all
Nanobodies retrieved from that panning should recog-
nize epitopes that are common in T. b. brucei AnTat 1.1Table 2
Adapted panning protocols
Selection Round 1
“A” T. b. brucei AnTat 1.1
“B” T. b. brucei AnTat 1.1
“C” T. b. rhodesiense ETat 1.2
“D” T. b. gambiense FEO
Phages from the library were selected each time on same T. b. brucei AnTatand T. evansi that originally infected the dromedary. For
the second set of screenings alternating coatings of
lysates of different Trypanosoma were used to retrieve
Nanobodies that are reactive to epitopes shared by all
these parasites (Table 2, selections “B–D”).
In selection “A”, three rounds of panning were
performed on T. b. brucei AnTat 1.1 lysate (Table 2)
with in each round an increasing number of washings to
effectively remove phages carrying nonspecific binders.
Enrichment of phages was observed from the second
round onwards. After round two and three, 48 individual
colonies were randomly picked for screening in phage
ELISA. All colonies that gave a high signal in phage
ELISA were further screened by PCR amplification of
their VHH insert, a HinfI RFLP on the PCR fragment
and sequence analysis. Seven different Nanobodies, i.e.
NbTRYP01, 02, 03, 04, 06, 07 and 08 were identified
(Fig. 2B). In addition to binding to antigens from the
T. b. brucei AnTat 1.1 lysate, these Nanobodies recog-
nize an epitope present in the T. evansi ITMAS and
T. evansiKenya lysate as well. However, no retention onRound 2 Round 3
T. b. brucei AnTat 1.1 T. b. brucei AnTat 1.1
T. vivax T. evansi ITMAS
T. evansi ITMAS T. vivax
T. evansi ITMAS T. b. rhodesiense Etat 1.2
1.1 lysate (“A”) or different total parasite lysate (“B”, “C”, “D”).
Table 3
Binding properties of Nanobodies isolated by panning on different Trypanosoma lysates
NbTRYP sVSG
T. b. brucei
AnTat 1.1
Lysate
T. b. brucei
AnTat 1.1
Lysate
T. evansi
ITMAS
Lysate
T. evansi
Kenya
Lysate
T. vivax
Lysate
T. b. rhodesiense
ETat 1.2
Lysate
T. b. gambiense
FEO
Lysate
T. congolense
Tc13
Lysate
Leishmania
01 − + + + ND ND ND ND ND
02 − ++ + + ND ND ND ND ND
03 − +++ + + ND ND ND ND ND
04 − +++ + + ND ND ND ND ND
06 − + + + ND ND ND ND ND
07 − +++ + + ND ND ND ND ND
08 − ++ + + ND ND ND ND ND
11 − +++ +++ ND +++ +++ ++ − −
12 − +++ +++ ND +++ ++ ++ − −
13 − ++ + ND − ++ + − −
14 − ++ +++ ND +++ ++ ++ − −
15 − +++ +++ ND +++ +++ +++ − −
16 − − +++ ND + + − − −
17 − + ++ ND + ++ + − −
Purified sVSG from T. b. brucei AnTat 1.1 or total parasite lysate was coated at 10 μg ml−1 in PBS. Bound recombinant phage particles presenting a
NbTRYP on their tip were detected by an anti-M13 horse-radish peroxidase conjugate. The OD at 405 nm was measured 15 min after addition of
substrate (ND = not determined, − b 2 times nonspecific signal, + N3 times nonspecific signal, ++ N5 times nonspecific signal, +++ N 7 times
nonspecific signal). The Leishmania lysate was used as a negative control in the experiment.
146 D. Saerens et al. / Journal of Immunological Methods 329 (2008) 138–150the T. b. brucei AnTat 1.1 sVSG was observed for these
binders in ELISA (Table 3).
Application of the second set of panning procedures
resulted in isolation of novel Nanobodies, pan-reactive
across the various trypanosomes. Four rounds of selec-
tions were carried out in immunotubes as compared to
microtiter plates for the first screening method, with in
each round a different lysate as coating (Table 2,
selections “B”, “C” and “D”). Specific enrichment of
phages starting from the second round was observed onFig. 5. The fluorescently labeled NbTRYP were incubated with 2×106 fixed T
T. b. brucei AnTat1.1) and negative control (Nbgraft) were also included.T. b. brucei AnTat 1.1 lysate, even for pannings “C” and
“D” that had never been selected on the T. b. brucei
AnTat 1.1 lysate. A similar enrichment for pan-reactive
Nanobodies in the phage pool was seen on the other
Trypanosoma lysates. After the second and third round
of selection, 120 randomly picked colonies were ana-
lyzed for producing virions that were binding to each
lysate. The HinfI RFLP and sequence analysis of the
VHH genes from these colonies revealed seven addi-
tional, distinct Nanobodies (NbTRYP11-17) interacting. b. brucei AnTat 1.1 parasites. Positive control (NbAn33 binding only
Table 4
Binding of different NbTRYP on T. b. brucei AnTat 1.1 and T. b.
brucei AnTar lysates, GPI-anchored membrane fraction (MF) of T. b.
brucei AnTat 1.1, or the solubilized VSG from T. b. brucei AnTat 1.1
(sVSG)
NbTRYP AnTat AnTar MF sVSG
02 ++ ++ + −
06 ++ ++ + −
07 ++ ++ ++ −
11 ++ ++ ++ −
12 ++ ++ + −
14 ++ ++ ++ −
15 + + + −
The OD at 405 nm was measured 15 min after addition of substrate
(− b 2 times nonspecific signal, + N 2 times nonspecific signal, ++ N 4
times nonspecific signal).
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dies only recognized a few Trypanosoma lysates, others
showed a broader specificity (Table 3).
All these Nanobodies apparently recognizing an
antigen occurring in several lysates (i.e., the NbTRYP
clones in Fig. 2B) were cloned into an expression vector,
produced and purified. Only the Nanobodies expressing
at levels above 1 mg protein per liter E. coli culture were
used for further analysis, i.e. NbTRYP02, 03, 06, 07, 11,
12, 13, 14, 15, and 17.
3.6. Characterization of the pan-reactive Nanobodies
by FACS
The pan-reactive Nanobodies were first assessed for
their ability to interact with accessible epitopes on the
surface of the parasite. Binding of fluorescently labeled
Nanobodies to parasites was analyzed by FACS (Fig. 5).
The T. b. brucei AnTat 1.1 parasites were stained upon
addition of NbTRYP02, 06, 11 and 14, indicating that
these Nanobodies recognize epitopes at the surface of
the parasite. Specific binding of these Nanobodies was
also observed on fixed T. b. gambiense ABBA, T. b.
rhodesiense ETat 1.2, T. evansi KETRI and
T. congolense Tc13 confirming their pan-reactive poten-
tial. Remarkably those Nanobodies bound T. congolense
Tc13 in FACS, whereas they failed to recognize their
cognate epitope within the lysate when screened by
ELISA (Table 3). This might be explained by the dif-
ference in epitope presentation during FACS and ELISA
experiments. In addition, only low binding signals were
observed for NbTRYP07 and 12, suggesting a low
affinity reaction and/or low density or restricted access
of the antigen on the parasite coat. Since NbTRYP02
and NbTRYP12 have a nearly identical amino acid
sequence, including that of their antigen-binding loops,it is highly likely that they recognize the same epitope.
Therefore, the different staining pattern of the parasites
by this latter pair of binders probably reflects a net
difference among these Nanobodies in their equilibrium
dissociation constant for the epitope. For NbTRYP03,
13, 15 and 17 there was no detectable staining of the
parasites when analyzed by FACS. This inaccessibility
suggests that their cognate antigens are most likely
present intracellularly or embedded in the parasites'
membrane.
The NbTRYP targeting was extended to include
living parasites because such binding tests are more
relevant for diagnostic or therapeutic validation of
Nanobodies. All NbTRYPs positive for fixed parasites
targeted equally well the living T. b. brucei AnTat 1.1.
3.7. Characterization of the pan-reactive Nanobodies
by ELISA
Normally, the sVSG from different trypanosome
lysates are expected to possess little sequence overlap,
hence the pan-reactive Nanobodies are unlikely to target
the VSG. To formally exclude the possibility that the
pan-reactive Nanobodies bind to sVSG, they were tested
for recognizing the sVSG from T. b. brucei MiTat 1.5,
T. b. brucei AnTat 1.1, T. b. rhodesiense ETat 1.2,
T. congolense Tc13, T. b. gambiense FEO and T. evansi
ITMAS. None of the Nanobodies scored positive in
ELISA, confirming that NbTRYP02, 06, 11 and 14 are
targeting a non-VSG type antigen(s) on the parasite
surface. Neither are these Nanobodies interacting with
the surface exposed antigens SRA (Radwanska et al.,
2002), ESAG6 (Pays et al., 2001) and ISG75 (Tran
et al., 2006) as none of these recombinant proteins were
recognized by the NbTRYPs.
Furthermore, binding to T. b. bruceiAnTar (procyclic
form) lysate and the GPI-anchored membrane fraction
of T. b. brucei AnTat 1.1 lysate was evaluated (Table 4).
Binding to the procyclic form of T. b. brucei was
observed for the NbTRYP02, 06, 07, 11, 12, 14, and 15,
which indicates that these Nanobodies recognize a
protein that is also expressed during the insect cycle of
the parasite. Moreover, a GPI-anchored component is
targeted by these Nanobodies as seen from positive
signal on the GPI-anchored membrane protein fraction.
Surprisingly, the latter fraction was targeted by
NbTRYP15, a Nanobody of which the fluorescently
labeled format failed to stain the whole parasites. It is
surmised that this Nanobody binds an antigen that is too
deeply buried in the coat to be visualized in FACS after
staining with a Nanobody although the antigen is
present on the membrane of the parasite.
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This study demonstrates the feasibility to isolate a
panel of Trypanosoma infectome-specific binders from
an infected dromedary without having a priori knowl-
edge of the proteins involved. Obviously, camelids also
succeed in raising an immune response against several
components of a proteome or infectome. It was shown
that the camelid Heavy-chain antibodies were respond-
ing to various epitopes of the Trypanosoma infectome,
and that the antigen-binding fragments, the Nanobodies,
of these Heavy-chain antibodies could be efficiently
cloned and selected.
The repertoire cloning of conventional antibodies,
e.g. in the form of scFv, involves several steps. First, two
independent PCRs are needed to amplify the VH and
VL. Secondly, these fragments have to be joined
randomly into one construct by a linker segment, either
by a splicing of overlap extension or by a two-step
cloning strategy. This scrambling of the individual VH
and VL from a pool and the presence of artificial VH–
VL combinations with decreased affinity for the original
antigen implies that large libraries need to be screened in
order to isolate the parental VH–VL combination, and
that many binders with sub-optimal affinity and stability
will be obtained. Therefore, it seems rather counter-
productive to first immunize an animal in order to opti-
mize and mature the antibodies for the target antigen,
and then to split the antigen-binding partners and to
scramble them in the following step. This VH–VL
scrambling is avoided by cloning the repertoire of the
camelid HCAbs the entire antigen-binding site of each
HCAb is encoded by one single exon, the VHH.
It is well established that the VSG is the most
abundant protein present on the parasite's surface
(Dubois et al., 2005) and, for classical antibodies, it is
an immuno-dominant antigen. Here we confirmed that
T. evansi elicited a strong VSG-specific Heavy-chain
antibody response in the infected dromedary as well.
Admittedly, the immune response, raised during immu-
nization with a parasite lysate or after a natural infection
with the living parasite, might have a different outcome
due to an active living parasite to host interplay.
Therefore, the Nanobodies retrieved from an infected
dromedary or after immunizing a dromedary with a total
proteome extract from the parasite could react to a
widely varying panel of antigens.
As expected, screening the Nanobody library cloned
from the infected dromedary on the purified sVSG from
T. evansi Kenya as bait yielded highly species-specific
binders. Interestingly, the panning of the same Nano-
body library with the total lysate of T. b. bruceiAnTat1.1 resulted in the selection of several binders that
associated with the lysate of T. evansi and at least as
strong, or stronger, with antigens in the T. b. brucei
lysate. Following an adapted panning protocol whereby
the bait was switched between proteome lysates of
different Trypanosoma species during the consecutive
rounds of selection allowed the identification of
different Nanobodies that recognize non-VSG antigens
present in multiple Trypanosoma species. Some of these
Nanobodies (e.g. NbTRYP02, -06, -07, -11, -12, -14)
clearly associated (to various extends) with an antigen
exposed on the surface of living parasites (as revealed
by FACS analysis). One particular Nanobody
(NbTRYP15) failed to react with fixed or living para-
sites when analyzed by FACS, although it reacted well
with the antigens within the GPI-anchored membrane
fraction (MF, Table 4) in an ELISA. It seems that this
Nanobody binds to a surface antigen, cryptic in intact
parasites. In contrast, the NbTRYP03, -13, -15 and -17,
apparently failed to interact with the intact parasites, or
GPI-attached membrane extracts (Table 4), however,
their cognate antigen was present in the total lysate from
the same parasite (Table 3). Therefore, the most obvious
explanation would be that these Nanobodies are di-
rected against intracellular antigens (or transmembrane
antigens).
In any case, by changing the antigen fraction during the
selectionswe have access to awide variety ofNanobodies,
some of which are strain-specific, whereas others are pan-
reactive Nanobodies, i.e. Nanobodies that recognize an
antigen common to various Trypanosoma species. With
sets of VSG-specific and pan-reactive Nanobodies at
hand, it becomes feasible to design a protocol for a precise
species typing within an infected individual. For example,
antibody micro-arrays could be applied for the specific
and sensitive detection of those components from an
infected individual (Wingren et al., 2005).
Apart from the employment of these Nanobodies for
a diagnostic test, a therapeutic utilization might be
envisaged as well. To arrive at a therapeutic anti-try-
panosome drug, one has to link a pan-reactive Nano-
body with a potent trypanocidal compound, such as
truncated human ApoLI. A potent trypanocidal drug
was generated by combining a truncated human ApoLI
fragment with an anti-T. b. rhodesiense Nanobody
(Baral et al., 2006). This Nanobody, i.e. NbAn33, rec-
ognizing specifically multiple trypanosome species, was
obtained by screening a Nanobody library from a
dromedary immunized with soluble VSG of T. b. brucei
AnTat 1.1 (Stijlemans et al., 2004). The NbAn33
targeted the high-mannose carbohydrate epitope present
on various VSG proteins. As indicated above, here we
149D. Saerens et al. / Journal of Immunological Methods 329 (2008) 138–150retrieved Nanobodies with a similar broad trypanosome-
specific range without having access to purified
antigens, neither for raising the immune response, nor
for the Nanobody selections.
Acknowledgements
This work was supported by the VIB, FWO-
Vlaanderen, DGOS-AT and by the Vrije Universiteit
Brussel (GOA-VUB & OZR-VUB). S.M. and D.S. are
Postdoctoral Fellows of the Research Foundation —
Flanders (FWO) and D.S. acknowledges financial
support from the Instituut voor de aanmoediging van
Innovatie door Wetenschap en Technologie in Vlaan-
deren (IWT-Vlaanderen).
References
Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R.,
Muyldermans, S., 1997. Selection and identification of single
domain antibody fragments from camel heavy-chain antibodies.
FEBS Lett. 414, 521.
Azzazy, H.M., Highsmith Jr., W.E., 2002. Phage display technology:
clinical applications and recent innovations. Clin. Biochem. 35, 425.
Baral, T.N., Magez, S., Stijlemans, B., Conrath, K., Vanhollebeke, B.,
Pays, E., Muyldermans, S., De Baetselier, P., 2006. Experimental
therapy of African trypanosomiasis with a nanobody-conjugated
human trypanolytic factor. Nat. Med. 12, 580.
Bertone, P., Snyder, M., 2005. Advances in functional protein
microarray technology. Febs. J. 272, 5400.
Chretien, J.P., Smoak, B.L., 2005. African trypanosomiasis: changing
epidemiology and consequences. Curr. Infect. Dis. Rep. 7, 54.
Conrath, K.E., Lauwereys, M., Galleni, M., Matagne, A., Frere, J.M.,
Kinne, J., Wyns, L., Muyldermans, S., 2001. Beta-lactamase
inhibitors derived from single-domain antibody fragments elicited
in the camelidae. Antimicrob. Agents Chemother. 45, 2807.
Cross, G.A., 1975. Identification, purification and properties of clone-
specific glycoprotein antigens constituting the surface coat of
Trypanosoma brucei. Parasitology 71, 393.
Cross, G.A., 1984. Release and purification of Trypanosoma brucei
variant surface glycoprotein. J. Cell. Biochem. 24, 79.
De Genst, E., Silence, K., Decanniere, K., Conrath, K., Loris, R.,
Kinne, J., Muyldermans, S., Wyns, L., 2006. Molecular basis for
the preferential cleft recognition by dromedary heavy-chain
antibodies. Proc. Natl. Acad. Sci. U. S. A. 103, 4586.
De Masi, F., Chiarella, P., Wilhelm, H., Massimi, M., Bullard, B.,
Ansorge, W., Sawyer, A., 2005. High throughput production of
mouse monoclonal antibodies using antigen microarrays. Proteo-
mics 5, 4070.
Donelson, J.E., 2003. Antigenic variation and the African trypano-
some genome. Acta Trop. 85, 391.
Dubois, M.E., Demick, K.P., Mansfield, J.M., 2005. Trypanosomes
expressing a mosaic variant surface glycoprotein coat escape early
detection by the immune system. Infect. Immun. 73, 2690.
Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F.,
Heremans, K., Frenken, L.G., Muyldermans, S., Wyns, L.,
Matagne, A., 2002. Single-domain antibody fragments with high
conformational stability. Protein. Sci. 11, 500.Farnaes, L., Ditzel, H.J., 2003. Dissecting the cellular functions of
annexin XI using recombinant human annexin XI-specific
autoantibodies cloned by phage display. J. Biol. Chem. 278,
33120.
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson,
G., Hamers, C., Songa, E.B., Bendahman, N., Hamers, R., 1993.
Naturally occurring antibodies devoid of light chains. Nature 363,
446.
Hof, D., Cheung, K., Roossien, H.E., Pruijn, G.J., Raats, J.M., 2005. A
novel subtractive antibody phage display method to discover
disease markers. Mol. Cell. Proteomics 5, 245.
Huang, S.H., Triche, T., Jong, A.Y., 2002. Infectomics: genomics and
proteomics of microbial infections. Funct. Integr. Genomics. 1,
331.
Hutchinson, O.C., Webb, H., Picozzi, K., Welburn, S., Carrington, M.,
2004. Candidate protein selection for diagnostic markers of
African trypanosomiasis. Trends Parasitol. 20, 519.
Kabat, E.A., Wu, T.T., Perry, H.M., Gottesman, K.S., Koeler, C., 1991.
Sequences of proteins of immunological interest. Publication 91.
Kashiwazaki, Y., Kanitpun, R., Suteeraparp, P., Boonchit, S., 2000. A
preliminary comparative study of a dipstick colloidal dye
immunoassay and two antigen-detection ELISAs for diagnosis of
Trypanosoma evansi infection in cattle. Vet. Res. Commun. 24,
533.
Kausmally, L., Waalen, K., Lobersli, I., Hvattum, E., Berntsen, G.,
Michaelsen, T.E., Brekke, O.H., 2004. Neutralizing human
antibodies to varicella–zoster virus (VZV) derived from a VZV
patient recombinant antibody library. J. Gen. Virol. 85, 3493.
Kramer, R.A., Marissen, W.E., Goudsmit, J., Visser, T.J., Clijsters-Van
der Horst, M., Bakker, A.Q., Jong, M.D., Jongeneelen, M., Thijsse,
S., Backus, H.H., Rice, A.B., Weldon, W.C., Rupprecht, C.E.,
Dietzschold, B., Bakker, A.B., de Kruif, J., 2005. The human
antibody repertoire specific for rabies virus glycoprotein as
selected from immune libraries. Eur. J. Immunol 35, 2131.
Lanham, S.M., Godfrey, D.G., 1970. Isolation of salivarian trypano-
somes from man and other mammals using DEAE-cellulose. Exp.
Parasitol. 28, 521.
Lauwereys, M., Arbabi Ghahroudi, M., Desmyter, A., Kinne, J.,
Holzer, W., De Genst, E., Wyns, L., Muyldermans, S., 1998. Potent
enzyme inhibitors derived from dromedary heavy-chain antibo-
dies. EMBO J. 17, 3512.
Ledeboer, A.M., Bezemer, S., de Hiaard, J.J., Schaffers, I.M., Verrips,
C.T., van Vliet, C., Dusterhoft, E.M., Zoon, P., Moineau, S.,
Frenken, L.G., 2002. Preventing phage lysis of Lactococcus lactis
in cheese production using a neutralizing heavy-chain antibody
fragment from llama. J. Dairy Sci. 85, 1376.
Ludewig, B., Krebs, P., Metters, H., Tatzel, J., Tureci, O., Sahin, U.,
2004. Molecular characterization of virus-induced autoantibody
responses. J. Exp. Med. 200, 637.
Mitchell, L.A., Pearson, T.W., 1986. Antibody responses in resistant
and susceptible inbred mice infected with Trypanosoma con-
golense. Immunology 57, 297.
Muyldermans, S., 2001. Single domain camel antibodies: current
status. J. Biotechnol. 74, 277.
Nakayama, M., Neri, D., Ohara, O., 2001. A new simplified method
for preparation of a synthetic phage antibody with practically
acceptable detection sensitivity on immunoblots. Hum. Antibodies
10, 55.
Parmley, S.F., Smith, G.P., 1988. Antibody-selectable filamentous fd
phage vectors: affinity purification of target genes. Gene 73, 305.
Pays, E., Lips, S., Nolan, D., Vanhamme, L., Perez-Morga, D., 2001.
The VSG expression sites of Trypanosoma brucei: multipurpose
150 D. Saerens et al. / Journal of Immunological Methods 329 (2008) 138–150tools for the adaptation of the parasite to mammalian hosts. Mol.
Biochem. Parasitol. 114, 1.
Pays, E., Vanhamme, L., Perez-Morga, D., 2004. Antigenic variation
in Trypanosoma brucei: facts, challenges and mysteries. Curr.
Opin. Microbiol. 7, 369.
Radwanska, M., Chamekh, M., Vanhamme, L., Claes, F., Magez, S.,
Magnus, E., de Baetselier, P., Buscher, P., Pays, E., 2002. The
serum resistance-associated gene as a diagnostic tool for the
detection of Trypanosoma brucei rhodesiense. Am. J. Trop. Med.
Hyg. 67, 684.
Reiche, N., Jung, A., Brabletz, T., Vater, T., Kirchner, T., Faller, G.,
2002. Generation and characterization of human monoclonal scFv
antibodies against Helicobacter pylori antigens. Infect. Immun.
70, 4158.
Rothe, A., Klimka, A., Tur, M.K., Pfitzner, T., Huhn, M., Sasse, S.,
Mallmann, P., Engert, A., Barth, S., 2004. Construction of phage
display libraries from reactive lymph nodes of breast carcinoma
patients and selection for specifically binding human single chain
Fv on cell lines. Int. J. Mol. Med. 14, 729.
Saerens, D., Kinne, J., Bosmans, E., Wernery, U., Muyldermans, S.,
Conrath, K., 2004. Single domain antibodies derived from
dromedary lymph node and peripheral blood lymphocytes sensing
conformational variants of prostate-specific antigen. J. Biol. Chem.
279, 51965.
Sakakibara, K., Sato, K., Iwasaki, T., Kitamura, K., Fukami, Y., 2005.
Generation of an antibody specific to Xenopus fertilized eggs by
subtractive immunization. Genes Cells 10, 345.
Schaffitzel, C., Hanes, J., Jermutus, L., Pluckthun, A., 1999. Ribosome
display: an in vitro method for selection and evolution of
antibodies from libraries. J. Immunol. Methods 231, 119.
Schell, D., Overath, P., 1990. Purification of the membrane-form
variant surface glycoprotein of Trypanosoma brucei. J. Chroma-
togr. 521, 239.
Silacci, M., Brack, S., Schirru, G., Marlind, J., Ettorre, A., Merlo, A.,
Viti, F., Neri, D., 2005. Design, construction, and characterizationof a large synthetic human antibody phage display library.
Proteomics 5, 2340.
Smith, G.P., Petrenko, V.A., 1997. Phage display. Chem. Rev. 97, 391.
Stijlemans, B., Conrath, K., Cortez-Retamozo, V., Van Xong, H.,
Wyns, L., Senter, P., Revets, H., De Baetselier, P., Muyldermans,
S., Magez, S., 2004. Efficient targeting of conserved cryptic
epitopes of infectious agents by single domain antibodies. African
trypanosomes as paradigm. J. Biol. Chem. 279, 1256.
Stijlemans, B., Baral, T.N., Guilliams, M., Brys, L., Korf, J., Drennan,
M., Van Den Abbeele, J., De Baetselier, P., Magez, S., 2007. A
glycosylphosphatidylinositol-based treatment alleviates trypano-
somiasis-associated immunopathology. J. Immunol. 179, 4003.
Tran, T., Claes, F., Dujardin, J.C., Buscher, P., 2006. The invariant
surface glycoprotein ISG75 gene family consists of two main
groups in the Trypanozoon subgenus. Parasitology 133, 613.
Tur, M.K., Rothe, A., Huhn, M., Goerres, U., Klimka, A., Stocker, M.,
Engert, A., Fischer, R., Finner, R., Barth, S., 2003. A novel
approach for immunization, screening and characterization of
selected scFv libraries using membrane fractions of tumor cells.
Int. J. Mol. Med. 11, 523.
Wernery, U., Kaaden, O.R., 2002. Infectious Diseases of Camelids,
Second edition. Blackwell Science, Berlin, Wein, p. 273.
Wingren, C., Steinhauer, C., Ingvarsson, J., Persson, E., Larsson, K.,
Borrebaeck, C.A., 2005. Microarrays based on affinity-tagged
single-chain Fv antibodies: sensitive detection of analyte in
complex proteomes. Proteomics 5, 1281.
Zampieri, S., Mahler, M., Bluthner, M., Qiu, Z., Malmegrim, K.,
Ghirardello, A., Doria, A., van Venrooij, W.J., Raats, J.M., 2003.
Recombinant anti-P protein autoantibodies isolated from a human
autoimmune library: reactivity, specificity and epitope recognition.
Cell. Mol. Life Sci. 60, 588.
Zijlstra, A., Testa, J.E., Quigley, J.P., 2003. Targeting the proteome/
epitome, implementation of subtractive immunization. Biochem.
Biophys. Res. Commun. 303, 733.
